Inflammasome activation in the liver: Focus on alcoholic and non-alcoholic steatohepatitis

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue , 2015, Pages S18-S23

  Szabo, Gyongyi ^a   Iracheta Vellve, Arvin ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; INFLAMMASOME; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; ENZYME INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; CELL SPECIFICITY; CELLS BY BODY ANATOMY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); ENZYME ACTIVATION; HUMAN; MEDIATOR RELEASE; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY MECHANISM; SHORT SURVEY; UPREGULATION; ANIMAL; DISEASE COURSE; FATTY LIVER; LIVER; LIVER DISEASES, ALCOHOLIC; METABOLISM;

ANIMALS; DISEASE PROGRESSION; ENZYME INHIBITORS; FATTY LIVER; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LIVER; LIVER DISEASES, ALCOHOLIC; UP-REGULATION;

EID: 84942820675     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.06.012     Document Type: Short Survey

References (45)

1. Thompson M.R., Kaminski J.J., Kurt-Jones E.A., Fitzgerald K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3(6):920-940.
2. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009, 183(2):787-791.
3. Franchi L., Eigenbrod T., Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009, 183(2):792-796.
4. Stehlik C., Fiorentino L., Dorfleutner A., Bruey J.M., Ariza E.M., Sagara J., et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med 2002, 196(12):1605-1615.
5. Stehlik C., Lee S.H., Dorfleutner A., Stassinopoulos A., Sagara J., Reed J.C. Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol 2003, 171(11):6154-6163.
6. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39(6):1003-1018.
7. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010, 10(12):826-837.
8. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117(14):3720-3732.
9. Ganz M., Csak T., Nath B., Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol 2011, 17(43):4772-4778.
10. Petrasek J., Bala S., Csak T., Lippai D., Kodys K., Menashy V., et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012, 122(10):3476-3489.
11. Lippai D., Bala S., Petrasek J., Csak T., Levin I., Kurt-Jones E.A., et al. Alcohol-induced IL-1beta in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol 2013, 94(1):171-182.
12. Petrasek J., Iracheta-Vellve A., Saha B., Satishchandran A., Kodys K., Fitzgerald K.A., et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease. J Leukoc Biol 2015, pii: jlb.3AB1214-590R [Epub ahead of print].
13. DeSantis D.A., Ko C.W., Liu Y., Liu X., Hise A.G., Nunez G., et al. Alcohol-induced liver injury is modulated by Nlrp3 and Nlrc4 inflammasomes in mice. Mediators Inflamm 2013, 2013:751374.
14. Kahlenberg J.M., Dubyak G.R. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol 2004, 286(5):C1100-C1108.
15. Katsnelson M.A., Rucker L.G., Russo H.M., Dubyak G.R. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol 2015, 194(8):3937-3952.
16. Iracheta-Vellve A., Petrasek J., Satishchandran A., Gyongyosi B., Saha B., Kodys K., et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol 2015, pii: S0168-8278(15)00405-5 [Epub ahead of print]. 10.1016/j.jhep.2015.06.013.
17. Rock K.L., Kataoka H., Lai J.J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol 2013, 9(1):13-23.
18. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327(5963):296-300.
19. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425(6957):516-521.
20. Lieber C.S., Jones D.P., Losowsky M.S., Davidson C.S. Interrelation of uric acid and ethanol metabolism in man. J Clin Invest 1962, 41:1863-1870.
21. Szabo G., Csak T. Inflammasomes in liver diseases. J Hepatol 2012, 57(3):642-654.
22. Petrasek J., Csak T., Ganz M., Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2013, 28(Suppl. 1):93-98.
23. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-185.
24. Michelotti G.A., Machado M.V., Diehl A.M. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013, 10(11):656-665.
25. Louvet A., Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 2015, 12(4):231-242.
26. Seton-Rogers S. Hepatocellular carcinoma: gender differences. Nat Rev Cancer 2014, 14(9):578.
27. Ganz M., Csak T., Szabo G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol 2014, 20(26):8525-8534.
28. Ganz M., Szabo G. Immune and inflammatory pathways in NASH. Hepatol Int 2013, 7(Suppl. 2):771-781.
29. Csak T., Pillai A., Ganz M., Lippai D., Petrasek J., Park J.K., et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int 2014, 34(9):1402-1413.
30. Ganz M., Bukong T.N., Csak T., Saha B., Park J.K., Ambade A., et al. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. J Transl Med 2015, 13:193. 10.1186/s12967-015-0552-7.
31. Csak T., Ganz M., Pespisa J., Kodys K., Dolganiuc A., Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54(1):133-144.
32. Guarda G., Dostert C., Staehli F., Cabalzar K., Castillo R., Tardivel A., et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009, 460(7252):269-273.
33. Mishra B.B., Rathinam V.A., Martens G.W., Martinot A.J., Kornfeld H., Fitzgerald K.A., et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 2013, 14(1):52-60.
34. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
35. Granowitz E.V., Clark B.D., Vannier E., Callahan M.V., Dinarello C.A. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 1992, 79(9):2356-2363.
36. Deree J., Martins J.O., Melbostad H., Loomis W.H., Coimbra R. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 2008, 63(3):321-328.
37. Marques L.J., Zheng L., Poulakis N., Guzman J., Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999, 159(2):508-511.
38. Sturniolo G.C., Di Leo V., Ferronato A., D'Odorico A., D'Inca R. Zinc supplementation tightens "leaky gut" in Crohn's disease. Inflamm Bowel Dis 2001, 7(2):94-98.
39. Sturniolo G.C., Fries W., Mazzon E., Di Leo V., Barollo M., D'inca R. Effect of zinc supplementation on intestinal permeability in experimental colitis. J Lab Clin Med 2002, 139(5):311-315.
40. Zhong W., McClain C.J., Cave M., Kang Y.J., Zhou Z. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol 2010, 298(5):G625-G633.
41. Wiezorek J.S., Brown D.H., Kupperman D.E., Brass C.A. Rapid conversion to high xanthine oxidase activity in viable Kupffer cells during hypoxia. J Clin Invest 1994, 94(6):2224-2230.
42. Kono H., Rusyn I., Bradford B.U., Connor H.D., Mason R.P., Thurman R.G. Allopurinol prevents early alcohol-induced liver injury in rats. J Pharmacol Exp Ther 2000, 293(1):296-303.
43. Silverman W.R., de Rivero Vaccari J.P., Locovei S., Qiu F., Carlsson S.K., Scemes E., et al. The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem 2009, 284(27):18143-18151.
44. Garay R.P., El-Gewely M.R., Labaune J.P., Richette P. Therapeutic perspectives on uricases for gout. Joint Bone Spine 2012, 79(3):237-242.
45. Kono H., Chen C.J., Ontiveros F., Rock K.L. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 2010, 120(6):1939-1949.